|
Variable
|
Multivariable Cox regression
|
|---|
|
Total cohort
|
BCLC 0/A
|
BCLC B/C
|
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
Age, years
|
1.03 (0.72–1.48)
|
0.868
|
1.08 (0.61–1.93)
|
0.791
|
0.79 (0.49–1.29)
|
0.343
|
|
Male gender
|
0.86 (0.53–1.40)
|
0.541
|
1.10 (0.51–2.37)
|
0.803
|
0.85 (0.44–1.65)
|
0.626
|
|
Platelet count, × 109/l
|
1.62 (1.10–2.38)
|
0.014
|
1.90 (1.02–3.53)
|
0.043
|
1.26 (0.75–2.11)
|
0.383
|
|
Prothrombin time, sec
|
1.00 (0.89–1.12)
|
0.938
|
0.92 (0.76–1.11)
|
0.362
|
1.07 (0.92–1.25)
|
0.379
|
|
Serum AFP, ng/ml
|
1.09 (0.80–1.49)
|
0.594
|
1.22 (0.72–2.05)
|
0.457
|
0.92 (0.61–1.39)
|
0.677
|
|
Tumor size, cm
|
1.71 (1.21–2.44)
|
0.003
|
1.95 (1.15–3.32)
|
0.014
|
1.58 (0.95–2.64)
|
0.079
|
|
ALBI score
|
1.62 (1.18–2.22)
|
0.003
|
2.29 (1.39–3.78)
|
0.001
|
1.42 (0.91–2.20)
|
0.122
|
|
Major hepatectomy
|
1.33 (0.93–1.88)
|
0.115
|
1.02 (0.53–1.95)
|
0.965
|
1.33 (0.86–2.08)
|
0.201
|
|
MVI
|
2.10 (1.49–2.97)
|
< 0.001
|
1.91 (1.13–3.01)
|
0.028
|
1.53 (0.89–2.83)
|
0.046
|
|
Differentiation grade
|
1.69 (1.24–2.30)
|
0.001
|
1.77 (1.08–2.89)
|
0.024
|
2.03 (1.28–3.23)
|
0.003
|
|
MELD score
|
0.98 (0.90–1.08)
|
0.727
|
0.98 (0.84–1.15)
|
0.803
|
1.00 (0.88–1.14)
|
0.989
|
- HR hazard ratio, CI confidence interval, BCLC Barcelona Clinic Liver Cancer, AFP α-fetoprotein, ALBI albumin-bilirubin, MVI microvascular invasion, MELD model for end-stage liver disease
